BACKGROUND: @entity5197 is one of the standard antiretroviral therapy options in treatment-experienced and -na  ve @entity1 . However, efficacy data from clinical practice are scarce. Therefore, the efficacy of @entity5197 -containing antiretroviral therapies in clinical practice was investigated retrospectively. METHODS: In all, 295 treatment-na  ve and -experienced @entity1 were analysed using two different cut-offs for virological failure (200 or 50 copies/ml). The response at week 24 and onwards was evaluated as a 'time to loss of virological response' analysis and estimated as a survival function. Additionally, dual therapy regimens ( @entity5197 plus boosted Protease inhibitor) were compared to standard combinations in experienced @entity1 performing a snapshot-analysis at weeks 24 and 48, as well as a time to loss of virological response analysis. RESULTS: A total of 86.2% of the 64 treatment-na  ve @entity1 maintained virological suppression using a cut-off 200 copies/ml (c/ml), while 67.7% maintained virological suppression with a 50   c/ml cut-off from week 24 until the end of observation. Among the 231 treatment-experienced @entity1 , 84.8% maintained virological suppression from week 24 onwards using a cut-off of 200   c/ml; and 71.0% using 50   c/ml, respectively. In the subgroup snapshot analysis at week 24, 98.3% (86.7% using a cut-off of 50   c/ml) and at week 48 93.3% (80.0%) of @entity1 responded to dual therapy. @entity1 who were receiving a standard background therapy responded in 88.3% (81.3%) at week 24 and in 86.0% (80.7%) at week 48. Differences were not significant. CONCLUSION: This study shows again the overall long-term efficacy of a @entity5197 -based antiretroviral therapy and furthermore gives reference for a comparable efficacy of dual and 25 nucleos(t)ide reverse transcriptase inhibitor-backbone regimens in experienced @entity1 on @entity5197 over a period of 48 weeks in a real-life cohort where @entity1 with severe comorbidities were included.

Efficacy of XXXX -containing regimens in antiretroviral-na  ve and -experienced individuals in routine clinical practice.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity5197 :: ('MESH:C507898', 'Chemical') :: ['Raltegravir']
@entity5197 :: (MESH:C507898,Chemical) :: ['Raltegravir']
